What Sprout Pharmaceuticals does

Sprout Pharmaceuticals is a U.S.-based specialty pharmaceutical company headquartered in Raleigh, North Carolina, that develops and commercializes treatments for female sexual dysfunction, with a single approved product: Addyi (flibanserin 100mg), a once-daily oral, non-hormonal therapy approved by the FDA in 2015 for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women and, as of December 2025, expanded to all women under 65 including postmenopausal women. Addyi operates via a centrally acting mechanism targeting serotonin, dopamine and norepinephrine pathways in the brain — differentiated from the peripherally acting blood-flow therapies used for male sexual dysfunction — and is supported by the largest clinical evidence base ever submitted for an FDA filing in women's sexual health, with over 13,000 participants (three times the data of any men's sexual health drug).

The company generates revenue exclusively through prescription sales of Addyi, dispensed across 70,000+ U.S. retail pharmacies and prescribed by 30,000+ U.S. healthcare professionals. Pricing is determined per prescription through the retail pharmacy network and patient insurance; no subscription or direct-to-consumer pricing is published. Sprout supports the HCP and patient ecosystem through three dedicated digital destinations — addyi.com (patient), addyihcp.com (healthcare provider) and sproutmedicalinfo.com (medical affairs) — and is led by founder/CEO Cindy Eckert, whose profile and advocacy have driven significant earned-media coverage (TIME 10 Most Influential Health and Life Science Companies 2026, TIME100 Health 2026, Oprah Daily Menopause O-wards 2026, The Pink Pill documentary on Paramount+, March 2026).

Name

Sprout Pharmaceuticals

Legal name

Sprout Pharmaceuticals, Inc.

Website

https://sproutpharmaceuticals.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Sprout Pharmaceuticals is a US specialty pharma that develops and commercializes Addyi (flibanserin), the first FDA-approved therapy for Hypoactive Sexual Desire Disorder in women under 65, dispensed via 70,000+ US retail pharmacies and prescribed by 30,000+ healthcare professionals.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• Women's sexual health
• HSDD treatment
• Prescription pharmaceuticals
• Flibanserin therapy
• Female sexual dysfunction

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Revenue model

1. Addyi (flibanserin) prescription sales: Revenue is generated through prescription sales of Addyi dispensed via the U.S. retail pharmacy network (70,000+ retail pharmacies) and prescribed by 30,000+ U.S. healthcare professionals. Treated as a one-time / per-prescription pharmaceutical product sale rather than a recurring subscription.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Sprout Pharmaceuticals develops, markets, and distributes Addyi (flibanserin 100mg), a once-daily oral, non-hormonal prescription therapy that is the first and only FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD) in women, originally approved in 2015 for premenopausal women and expanded in December 2025 to include postmenopausal women under 65. The company supplements the prescription drug with patient education, healthcare-provider prescribing resources, and medical-information support through dedicated websites (addyi.com, addyihcp.com, sproutmedicalinfo.com).

Product overview

Sprout Pharmaceuticals is a single-product specialty pharmaceutical company built around Addyi (flibanserin 100mg), its FDA-approved once-daily oral treatment for Hypoactive Sexual Desire Disorder (HSDD) — initially approved in 2015 for premenopausal women and expanded in December 2025 to postmenopausal women under 65. Rather than a platform-plus-modules architecture, Sprout's offering centers on the single branded therapy Addyi, supported by three dedicated digital resources that function as sub-offerings around the core product: the consumer-facing Addyi Patient Website (addyi.com), the prescriber-facing Addyi HCP Website (addyihcp.com), and the medical-affairs Sprout Medical Information site (sproutmedicalinfo.com). Together these elements deliver patient education, HCP clinical resources, and medical/scientific information, while broader brand initiatives (such as the "I Believe in Pink" campaign and the March 2026 Paramount+ premiere of "The Pink Pill" documentary) extend Addyi's market presence.

Differentiator

Problem solved

Functional benefit

Brands

• Addyi: Addyi (flibanserin) is Sprout Pharmaceuticals' flagship prescription drug — the first FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD) in women, originally approved in 2015 for premenopausal women and expanded in December 2025 to include postmenopausal women under 65.

Products and services

• Addyi (flibanserin 100mg) Addyi (flibanserin 100mg) is Sprout's flagship once-daily oral, non-hormonal prescription therapy FDA-approved for Hypoactive Sexual Desire Disorder (HSDD) in women under 65 — originally approved in 2015 for premenopausal women and expanded in December 2025 to postmenopausal women under 65. It acts on central serotonin receptors to address the brain-based root cause of low sexual desire and is the first and only FDA-approved treatment for HSDD in women.

Quantifiable outcome

• 13,000+ clinical trial participants — 3x the data submitted for any men's sexual health drug
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered flagship and minor.

• Paramount+ (The Pink Pill documentary)flagshipGTM or Marketing PartnerParamount+ premiered "The Pink Pill" documentary in March 2026, chronicling Sprout Pharmaceuticals' fight to bring the first FDA-approved women's libido treatment to market. The documentary is used as a major brand and advocacy asset, alongside founder Cindy Eckert's profile and the December 2025 expanded FDA approval.
• Harvard Business School Healthcare Club (Women's Health Summit)minorGTM or Marketing PartnerSprout Pharmaceuticals' founder/CEO Cindy Eckert delivered the keynote at Harvard Business School's 2025 Women's Health Summit (Nov 2025), discussing the development of the first FDA-approved treatment for low sexual desire in women and its impact on healthcare equity and investment.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Palatin Technologies: Palatin Technologies developed and commercializes Vyleesi (bremelanotide), the other FDA-approved prescription therapy for HSDD in premenopausal women. It is the most directly comparable competitor to Sprout in the female sexual dysfunction category.

Emerging players

• Dare Bioscience: Dare Bioscience is a clinical-stage women's health company with pipeline programs targeting female sexual arousal and desire disorders. It is an emerging competitor in the same therapeutic area where Sprout's Addyi is the approved incumbent.
• Evofem Biosciences: Evofem Biosciences commercialized Phexxi, a non-hormonal women's reproductive health product, and has explored adjacent women's sexual and reproductive health indications. It is an emerging player addressing overlapping women's health HCPs and patients.
• Mithra Pharmaceuticals: Mithra Pharmaceuticals is a European women's health company focused on contraception, menopause, and fertility. It is an emerging cross-Atlantic player in women's sexual and reproductive health, with adjacent therapeutic and commercial overlap.

Broad incumbents

• Organon & Co. Organon is a global women's health-focused pharmaceutical company spun out of Merck, with broad franchises across contraception, fertility, and menopause. It is a broad incumbent competitor in women's health that overlaps with Sprout's prescriber and patient base.
• TherapeuticsMD (now part of Padagis): TherapeuticsMD commercialized branded women's health products including therapies in menopause and sexual health before being acquired by Padagis. It is a broad incumbent in the women's reproductive and sexual health category overlapping with Addyi's prescriber base.
• Hologic: Hologic is a large women's-health-diagnostics and surgical-products company with a strong OB-GYN sales channel. While not directly competing with Addyi, it shares the same HCP customer base (OB-GYNs and women's health practitioners) that Sprout relies on for Addyi prescribing.
• Bayer (Pharmaceuticals): Bayer is a global pharmaceutical company with a women's health franchise spanning contraception and menopausal health. As a broad incumbent in women's health, it competes for the same HCP attention and formulary slots that Sprout's Addyi depends on.
• Pfizer: Pfizer historically developed and sold flibanserin internationally and operates a large women's health and primary-care commercial footprint. As the originator's commercialization partner and a broad incumbent, it is a relevant benchmark for Sprout's category dynamics.
• AbbVie: AbbVie operates large women's health and primary-care commercial channels and is a benchmark specialty pharma with strong HCP relationships. While Addyi is not in AbbVie's portfolio, AbbVie is a relevant scale and channel benchmark for Sprout's specialty-pharma commercial model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SproutPharma
• Facebookfacebook.com/sproutpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sprout Pharmaceuticals